[Below are the Areas of Interest for consideration for GSK’s Assets:]

[For belantamab mafodotin these include (updated December 2025):]
Combination Therapies:
Belamaf in combination with novel treatment options (e.g. CeLMoDs) in late-stage development in Multiple Myeloma where there is no ongoing research
• Induction with T-cell engagers followed by low-dose belamaf maintenance therapy
• Belamaf as bridging therapy prior to T-Cell engagers (e.g. CAR-T).
• Innovative combinations with a strong scientific rationale aimed at addressing areas of high unmet need.

Additional Therapeutic Targets
BCMA expressing malignancies (advanced amyloidosis in Cardiac 3b in both ND and RR ALA).

Pipeline asset(s) proposals may be considered where there is strong rational and data delivery aligns with clinical development of the asset.


[For Momelotinib these include (updated January 2026):]

Combination of Momelotinib with novel clinical stage assets with disease modifying potential, not limited to:

•   Anti-HJV (e.g., DISC-0974)
•   Anti-CALR therapies
•   MDM2 inhibitors (e.g., Navtemadlin)
•   Telomerase inhibitors (e.g., Imetelstat)
•   TGF modulators (e.g., elritercept)
•   CK0804

Note: Proposals to address other hematologic malignancies may be considered for those with extraordinary scientific rationale (case-by-case)
Combination strategies in VEXAS syndrome:
•   IL-1 / IL-6 inhibitors
•   HMAs (oral)
•   Next-generation targeted therapies

[For Dostarlimab these include (updated June 2026):]

Endometrial Cancer
1.   Translational research on anti-PD-(L)1 resistance
2.   ctDNA clinical utility in EC and for IO monitoring & treatment optimization
3.   IO combination approaches for MMRp/MSS EC

GI
1.   Stage I and II dMMR/MSI-H rectal cancer
2.   Optimal duration of therapy (i.e. retreatment)
3.   Investigation of adjuvant IO in dMMR/MSI-H locally advanced colon cancer
4.   Investigation of optimal clinical staging techniques and improvements in locally advanced colon cancer

Head and Neck
1.   Investigation of novel combinations (e.g. B7H3)
2.   Investigation of nasopharyngeal carcinoma